{"id":"erenumab-auto-injector","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3833329","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the CGRP receptor, erenumab prevents the action of CGRP, a molecule involved in the transmission of pain signals. This mechanism is thought to be effective in treating migraines.","oneSentence":"Erenumab is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:51:34.807Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of migraine in adults"}]},"trialDetails":[{"nctId":"NCT04084314","phase":"PHASE4","title":"Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-09-30","conditions":"Migraine, Migraine Disorders, Migraine Headache","enrollment":701},{"nctId":"NCT04152434","phase":"","title":"Treatment of Chronic Migraine With Erenumab Alone or as an Add on Therapy","status":"COMPLETED","sponsor":"Clinique des Céphalées de Montréal","startDate":"2019-04-01","conditions":"Refractory Chronic Migraine","enrollment":158}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Botox, and oral migraine preventives"],"phase":"phase_2","status":"active","brandName":"Erenumab Auto-Injector","genericName":"Erenumab Auto-Injector","companyName":"Clinique des Céphalées de Montréal","companyId":"clinique-des-c-phal-es-de-montr-al","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erenumab is a human monoclonal antibody that targets the calcitonin gene-related peptide (CGRP) receptor. Used for Prevention of migraine in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}